Skye Bioscience, Inc.
SKYE · XNASCIK 1516551fmd_11HGJVBXZW4PMA8YW9HJZ0NRSHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Nov 01, 2011 to Jun 30, 2026, 61 periods
Latest annual · FY2025
Millions- Operating income
- (58)
- Net income
- (56)
- Free cash flow
- (43)
Latest quarter · Q2 FY2026
Millions- Operating income
- (11)
- Net income
- (11)
- Free cash flow
- (7)
Daily close · SKYEIEX trades only
Oct 15, 2025 to Nov 10, 2026 · 250 sessions0.76 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Skye Bioscience, Inc. (SKYE) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$58.2 million | -$30.2 million | 10-K 2026-03-10 · proof | |
| Net income | -$55.9 million | -$26.6 million | 10-K 2026-03-10 · proof | |
| Cash from operating activities | -$43.1 million | -$25.2 million | 10-K 2026-03-10 · proof | |
| Free cash flow | -$43.1 million | -$26.8 million | 10-K 2026-03-10 · proof | |
| Total assets | $28.3 million | $72.8 million | -61.1% | 10-K 2026-03-10 · proof |
| Total liabilities | $8.3 million | $4.6 million | +79.7% | 10-K 2026-03-10 · proof |
| Cash and cash equivalents | $5.9 million | $68.4 million | -91.4% | 10-K 2026-03-10 · proof |
- What was Skye Bioscience, Inc. (SKYE)'s operating income in fiscal 2025?
- Skye Bioscience, Inc. (SKYE) reported operating income of -$58.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$30.2 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was Skye Bioscience, Inc. (SKYE)'s net income in fiscal 2025?
- Skye Bioscience, Inc. (SKYE) reported net income of -$55.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$26.6 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was Skye Bioscience, Inc. (SKYE)'s cash from operating activities in fiscal 2025?
- Skye Bioscience, Inc. (SKYE) reported cash from operating activities of -$43.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$25.2 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was Skye Bioscience, Inc. (SKYE)'s free cash flow in fiscal 2025?
- Skye Bioscience, Inc. (SKYE) reported free cash flow of -$43.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$26.8 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are Skye Bioscience, Inc. (SKYE)'s total assets?
- As of Dec 31, 2025, Skye Bioscience, Inc. (SKYE) reported total assets of $28.3 million, against $72.8 million a year earlier (-61.1%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are Skye Bioscience, Inc. (SKYE)'s total liabilities?
- As of Dec 31, 2025, Skye Bioscience, Inc. (SKYE) reported total liabilities of $8.3 million, against $4.6 million a year earlier (+79.7%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are Skye Bioscience, Inc. (SKYE)'s cash and cash equivalents?
- As of Dec 31, 2025, Skye Bioscience, Inc. (SKYE) reported cash and cash equivalents of $5.9 million, against $68.4 million a year earlier (-91.4%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:SKYE&period_type=annual&limit=5"Information only, not investment advice.